🇺🇸 FDA
Patent

US 11993644

Antigen binding molecules targeting SARS-CoV-2

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11993644 (Antigen binding molecules targeting SARS-CoV-2) held by Generate Biomedicines, Inc. expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Generate Biomedicines, Inc.
Grant date
Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K31/13, A61K31/215